SAL008 / Shenzhen Salubris 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAL008 / Shenzhen Salubris
2022-000339-21: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer Un estudio de fase 1/2, multicéntrico, abierto, de escalada de dosis y expansión de dosis de JK08 en pacientes con cáncer localmente avanzado o metastásico no resecable

Not yet recruiting
1/2
137
Europe
JK08, Solution for injection
Salubris Biotherapeutics, Inc., Salubris Biotherapeutics, Inc.
Unresectable Locally Advanced or Metastatic Cancer Cáncer localmente avanzado o metastásico no resecable, Unresectable Locally Advanced or Metastatic Cancer Cáncer localmente avanzado o metastásico no resecable, Diseases [C] - Cancer [C04]
 
 
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAL008 / Shenzhen Salubris
2022-000339-21: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer Un estudio de fase 1/2, multicéntrico, abierto, de escalada de dosis y expansión de dosis de JK08 en pacientes con cáncer localmente avanzado o metastásico no resecable

Not yet recruiting
1/2
137
Europe
JK08, Solution for injection
Salubris Biotherapeutics, Inc., Salubris Biotherapeutics, Inc.
Unresectable Locally Advanced or Metastatic Cancer Cáncer localmente avanzado o metastásico no resecable, Unresectable Locally Advanced or Metastatic Cancer Cáncer localmente avanzado o metastásico no resecable, Diseases [C] - Cancer [C04]
 
 
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26

Download Options